Cargando…
P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY.
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428728/ http://dx.doi.org/10.1097/01.HS9.0000969144.75498.e6 |
| _version_ | 1785090538767122432 |
|---|---|
| author | Moshe, Yakir Levi, Shai Neeman, Miri Gat, Roi Levi, Mor Eilati, Nili Shragai, Tamir Basood, May Segman, Yafit Baron, Yaeli Luttwak, Efrat Neuman, Tsipora Vitkon, Roy Mittelman, Moshe Avivi, Irit |
| author_facet | Moshe, Yakir Levi, Shai Neeman, Miri Gat, Roi Levi, Mor Eilati, Nili Shragai, Tamir Basood, May Segman, Yafit Baron, Yaeli Luttwak, Efrat Neuman, Tsipora Vitkon, Roy Mittelman, Moshe Avivi, Irit |
| author_sort | Moshe, Yakir |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428728 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104287282023-08-17 P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY. Moshe, Yakir Levi, Shai Neeman, Miri Gat, Roi Levi, Mor Eilati, Nili Shragai, Tamir Basood, May Segman, Yafit Baron, Yaeli Luttwak, Efrat Neuman, Tsipora Vitkon, Roy Mittelman, Moshe Avivi, Irit Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428728/ http://dx.doi.org/10.1097/01.HS9.0000969144.75498.e6 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Moshe, Yakir Levi, Shai Neeman, Miri Gat, Roi Levi, Mor Eilati, Nili Shragai, Tamir Basood, May Segman, Yafit Baron, Yaeli Luttwak, Efrat Neuman, Tsipora Vitkon, Roy Mittelman, Moshe Avivi, Irit P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY. |
| title | P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY. |
| title_full | P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY. |
| title_fullStr | P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY. |
| title_full_unstemmed | P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY. |
| title_short | P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY. |
| title_sort | p560: improvement in overall and relapse free survival of aml patients over the age of 75 since the approval of venetoclax in a real-world single center study. |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428728/ http://dx.doi.org/10.1097/01.HS9.0000969144.75498.e6 |
| work_keys_str_mv | AT mosheyakir p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy AT levishai p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy AT neemanmiri p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy AT gatroi p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy AT levimor p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy AT eilatinili p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy AT shragaitamir p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy AT basoodmay p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy AT segmanyafit p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy AT baronyaeli p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy AT luttwakefrat p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy AT neumantsipora p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy AT vitkonroy p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy AT mittelmanmoshe p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy AT aviviirit p560improvementinoverallandrelapsefreesurvivalofamlpatientsovertheageof75sincetheapprovalofvenetoclaxinarealworldsinglecenterstudy |